Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

ard of care regimen for each genotype. Preliminary safety and antiviral activity data from the 4-week combination treatment period are anticipated during the third quarter of 2008.

"Based on our pharmacokinetic modeling, we believe that the R7128 1000mg BID combination dosing regimen in Cohort 3 may be able to achieve similar antiviral responses as were demonstrated with R7128 1500mg BID in Cohort 2," stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "Cohort 4 will be the first administration of R7128 in patients with HCV genotypes 2 or 3, and thus will serve as proof-of-concept for this population who we believe represent an area of great unmet medical need. If R7128 shows activity in HCV genotype 2 or 3 patients, this would demonstrate a distinct clinical attribute of nucleoside polymerase inhibitors."

Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from a Phase 1 oral single ascending dose study of R7128 in 46 healthy male volunteers showed that R7128 was generally well tolerated with no serious adverse events in doses up to 9000 mg.

In a Phase 1 study, R7128 demonstrated potent, dose-dependent antiviral activity across four genotype 1 prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstra
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or ... of $125 million aggregate principal amount of 3.75% Convertible ... offered and sold only to qualified institutional buyers pursuant ... as amended (the "Securities Act"). The Notes ... year, payable semiannually in arrears on June 15 and ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... March 5, 2012  RoundTable Healthcare Partners ("RoundTable"), an ... healthcare industry, announced today that Kent J. Davies ... RoundTable III Platform Development Corporation ("RPDC"), a Fund ... focus his attention on the identification and development ...
... -- Database101.com, a leading provider of email marketing, ... businesses and salespeople, will now offer its mailing lists and ... for marketers and salespeople. "Many marketers and small ... finding new ways to market successfully" said Vin Gupta, founder ...
Cached Medicine Technology:RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation 2Database101.com Offers Hot Sales Leads & Email Lists, ONLINE, with NO Minimum Order! 2
(Date:12/20/2014)... December 20, 2014 Weddingshe.com has recently ... launched a site-wide promotion of special occasion dresses for ... popular supplier of special occasion dresses for global women. ... with big discounts, up to 80% off. Among the ... Sequins Short Sweet 16 Dress) is very popular. What’s ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress wholesaler and retailer, ... for 2015. Great discounts are now offered on all ... get a discount, up to 80% off, when they ... 30, 2015. , VogueQueen.com has recently released its new ... promotion. Many customers worldwide like VogueQueen’s special designs which ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... 2014 Recently, AngelWeddingDress.com has introduced its ... for the coming Christmas. In the promotion, all buyers ... , “We have something special for the women who ... season. Moreover, our new collections of 2015 dresses have ... now at greatly discounted prices. Visit our website now ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... ANGELES, Oct. 3 Pink tags will be ... the supermarket chain partners,with vendors and suppliers to ... Throughout the month, pink tags can be found ... identify participating products,customers can purchase to support breast ...
... Interested in Stopping their Periods, But Unsure,About Medical Implications, ... of,women in a national survey say that they are ... aren,t sure if it,s safe. Yet when,physicians are polled, ... menstruation is, in fact, medically safe and,acceptable. The survey ...
... than the two thirds of the women in a ... their menstrual periods but many of them arent sure ... percent say that continuous oral contraceptive therapy to suppress ... survey results were presented by Kurt Barnhart MD, MSCE ...
... QUINCY, Mass., Oct. 3 The Stop & Shop Supermarket,Company, ... $75,000 to,Susan G. Komen for the Cure with the Pink ... Month," said Stop & Shop/Giant,Consumer Advisor Andrea Astrachan, "and by ... Giant, customers can support the fight against,breast cancer and help ...
... Inverness Medical,Innovations (Amex: IMA ) today announced ... both core laboratory and point of care,diagnostic testing products ... Inverness will pay an earn out up to a ... had,revenues of approximately $29.5m in 2006 and has been ...
... Workers in PA, MI, IL, FL, OH, MD, WI, WA Join Forces in, ... Equity ... Buyout, WASHINGTON, Oct. 3 ... union today,is launching a multi-state grassroots campaign calling on global buyout,giant the Carlyle ...
Cached Medicine News:Health News:Ralphs 'Pink Tag' Campaign to Raise $170,000 for Breast Cancer Awareness in October 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 3Health News:Differing attitudes found between women and doctors concerning menstrual suppression 2Health News:Stop & Shop and Giant Food Join General Mills in Pink for the Cure 2Health News:Inverness Medical Innovations Acquires Bio-Stat Healthcare Group 2Health News:SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nation's Largest Nursing Home Chain 2
... The TL-100 uses technology that takes ... by automatically detecting and reading them. It ... recording the results, mark lenses as you ... contact lenses. Easy to use, the TL-100 ...
... The Kowa RC-XV3 camera is ... The automatic exposure system, ... sensitivity, the 2.5~300ws watt indication ... handling are the basic features ...
FF 450plus fundus camera for 35mm photography. Upgradeable basic instrument for brilliant image quality....
The new TRC-NW6 non-mydriatic retinal camera is the ideal instrument for the growing market in telemedicine and diabetic screening....
Medicine Products: